Saturday, February 10, 2018

Jerusalem, Israel HQed Generic Drug Co Teva Pharmaceutical Industries, Ltd 4Q 2017 Revenues Were Down 16% From the 4Q 2016 and 4Q 2017 Gross Profit Was Down 25% ....................................................................................... 4Q 2017 Pretax Goodwill Impairment Charges Were $11.0 Bil and Other Pretax Asset Impairment and Restructuring Charges Totalled $3.9 Bil, Resulting in a 4Q 2017 Pretax Loss of $13.2 Bil ....................................................................................... Teva Recorded a 4Q 2017 Income Tax Benefit of $1.0 Bil Resulting From the Puzzling, Very Lucrative US Federal Income Tax Debt Forgiveness Feature in the US Trump Tax Cuts Act